ASH Annual Meeting

ASH Annual Meeting

Highlights and interviews from the American Society of Hematology’s Annual Meeting

Ibrutinib + Rituximab Benefits Patients With Pre-Treated Lymphoma and Leukemia

The combination of ibrutinib and rituximab is a promising treatment option for patients with relapsed or refractory blood cancers, according to results of two...

PD-1 Checkpoint Inhibitors Harness the Immune System to Treat Lymphomas

A new class of drugs, known as immune checkpoint inhibitors, is providing new perspective on how to treat relapsed and refractory lymphomas, according to...

CAR T Therapies: Engineering a Breakthrough in Lymphoma and Leukemia Treatment

Novel therapies that harness the body’s own immune cells to attack cancer cells took center stage at this year’s annual meeting. Across a variety of...

Venetoclax Plus Low-Dose Cytarabine Safe and Effective in Older Patients With Acute Myeloid Leukemia

The combination of the selective BCL-2 inhibitor venetoclax and low-dose cytarabine (LDAC) is a safe, effective option in older patients with acute myeloid leukemia...

ASH 2014 Annual Meeting Preview: The Rising Cost of Medical Care

Understanding the Problems and Exploring Solutions Health-care spending in the United States is a growing problem: in 2011, health-care spending was estimated at $2.7 trillion,...

2014 ASH Annual Meeting: Late But Certainly Not Least…

This year’s six late-breaking abstracts feature innovative research in preventing bleeding risk, better prediction tools in Hodgkin lymphoma, and new approaches for high-risk, difficult-to-treat...
Advertisement

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.